RU2671970C2 - Лиганды рецептора нейротензина - Google Patents

Лиганды рецептора нейротензина Download PDF

Info

Publication number
RU2671970C2
RU2671970C2 RU2015127086A RU2015127086A RU2671970C2 RU 2671970 C2 RU2671970 C2 RU 2671970C2 RU 2015127086 A RU2015127086 A RU 2015127086A RU 2015127086 A RU2015127086 A RU 2015127086A RU 2671970 C2 RU2671970 C2 RU 2671970C2
Authority
RU
Russia
Prior art keywords
compound
formula
group
active radionuclide
acceptor
Prior art date
Application number
RU2015127086A
Other languages
English (en)
Russian (ru)
Other versions
RU2015127086A (ru
Inventor
Франк ОСТЕРКАМП
Кристиане СМЕРЛИНГ
Ульрих РАЙНЕКЕ
Кристиан ХААЗЕ
Ян УНГЕВИСС
Original Assignee
3Б Фармасьютикалз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3Б Фармасьютикалз Гмбх filed Critical 3Б Фармасьютикалз Гмбх
Publication of RU2015127086A publication Critical patent/RU2015127086A/ru
Application granted granted Critical
Publication of RU2671970C2 publication Critical patent/RU2671970C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2015127086A 2012-12-07 2013-12-06 Лиганды рецептора нейротензина RU2671970C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12008208.6A EP2740726A1 (en) 2012-12-07 2012-12-07 Neurotensin receptor ligands
EP12008208.6 2012-12-07
PCT/EP2013/003700 WO2014086499A1 (en) 2012-12-07 2013-12-06 Neurotensin receptor ligands

Publications (2)

Publication Number Publication Date
RU2015127086A RU2015127086A (ru) 2017-01-11
RU2671970C2 true RU2671970C2 (ru) 2018-11-08

Family

ID=47355771

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015127086A RU2671970C2 (ru) 2012-12-07 2013-12-06 Лиганды рецептора нейротензина

Country Status (20)

Country Link
US (3) US10961199B2 (enExample)
EP (3) EP2740726A1 (enExample)
JP (2) JP6576828B2 (enExample)
KR (1) KR102290803B1 (enExample)
CN (2) CN109320502B (enExample)
AU (1) AU2013354422B2 (enExample)
BR (1) BR112015012530B1 (enExample)
CA (1) CA2893605C (enExample)
DK (2) DK3712131T3 (enExample)
ES (2) ES2941629T3 (enExample)
FI (1) FI3712131T3 (enExample)
HU (2) HUE050388T2 (enExample)
IL (1) IL239080B (enExample)
MX (1) MX370354B (enExample)
PL (2) PL3712131T3 (enExample)
PT (2) PT3712131T (enExample)
RU (1) RU2671970C2 (enExample)
SG (2) SG10201704564QA (enExample)
WO (1) WO2014086499A1 (enExample)
ZA (1) ZA201503446B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015273934B2 (en) * 2014-06-10 2020-08-20 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954934A1 (en) * 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954933A1 (en) * 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
CN108473541B (zh) * 2015-11-24 2023-05-12 特拉斯福特普拉斯公司 通过受体介导的化学疗法治疗癌症的肽化合物和肽缀合物
EP3279197A1 (en) * 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
IL324632A (en) 2016-12-01 2026-01-01 Regeneron Pharma Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
CN110650974B (zh) 2017-02-10 2024-04-19 瑞泽恩制药公司 用于免疫-pet成像的放射性标记的抗-lag3抗体
MY197688A (en) 2017-07-24 2023-07-05 Regeneron Pharma Anti-cd8 antibodies and uses thereof
WO2021005125A1 (en) * 2019-07-08 2021-01-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
JP7750828B2 (ja) 2019-09-16 2025-10-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質
CN111875667B (zh) * 2020-07-16 2021-12-21 南方科技大学 有机金属螯合物及其制备方法与应用、探针
MX2023004715A (es) * 2020-10-22 2023-05-10 Nihon Mediphysics Co Ltd Metodo para producir un complejo de circonio radioactivo.
IL307632A (en) * 2021-04-23 2023-12-01 Fusion Pharmaceuticals Inc Cancer treatment methods
CA3220010A1 (en) * 2021-05-13 2022-11-17 The General Hospital Corporation Molecular probes for in vivo detection of aldehydes
EP4355377A4 (en) * 2021-06-16 2025-05-07 Fusion Pharmaceuticals Inc. COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND, GEMCITABINE AND NAB-PACLITAXEL
WO2022261770A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and folfirinox
WO2022266357A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and napox
CA3249925A1 (en) * 2022-01-28 2023-08-03 Fusion Pharmaceuticals Inc. Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy
IL314786A (en) * 2022-02-18 2024-10-01 Full Life Tech Hk Limited Compounds and radioligands for targeting neurotensin receptor and uses thereof
WO2023215778A1 (en) * 2022-05-03 2023-11-09 The University Of North Carolina At Chapel Hill Development of ntsr targeted agents for imaging and therapy applications
US12091454B2 (en) 2022-12-28 2024-09-17 Development Center For Biotechnology Humanized anti-human neurotensin receptor 1 antibodies and their uses
WO2025144920A1 (en) * 2023-12-28 2025-07-03 Radionetics Oncology, Inc. Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof
WO2025146126A1 (en) * 2024-01-04 2025-07-10 Full-Life Technologies Hk Limited Preparation method of compounds targeting neurotensin receptor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2066317C1 (ru) * 1990-08-20 1996-09-10 Санофи Производные амидопиразолов или их соли с органическими или минеральными кислотами или с органическими или неорганическими основаниями и фармацевтическая композиция, обладающая ингибирующей активностью в отношении нейротензина
RU2195455C2 (ru) * 1995-04-11 2002-12-27 Санофи-Синтелябо Замещенные 1-фенил-3-карбоксамиды и их фармацевтически приемлемые соли, способ их получения, промежуточные соединения и фармацевтическая композиция на их основе, обладающая сродством к человеческим рецепторам нейротензина
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
WO2011156557A2 (en) * 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110321A (en) 1976-07-12 1978-08-29 Folkers Karl Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity
US4425269A (en) 1982-06-07 1984-01-10 Merck & Co., Inc. Metabolically protected analogs of neurotensin
US4439359A (en) 1982-07-02 1984-03-27 Merck & Co., Inc. Cyclic octapeptide analogs of neurotensin
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
CA2086453A1 (en) 1992-12-30 1994-07-01 Mcgill University Marker for neurotensin receptor
US5407916A (en) 1993-02-16 1995-04-18 Warner-Lambert Company Neurotensin mimetics as central nervous system agents
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
CA2183421A1 (en) 1994-02-18 1995-08-24 John Mertens Labelled peptide compounds
US6054557A (en) 1995-04-04 2000-04-25 Advanced Bioconcept (1994) Ltd. Fluorescent peptides
WO1996031531A2 (en) 1995-04-04 1996-10-10 Advanced Bioconcept, Inc. Fluorescent peptides
WO1997004311A2 (en) 1995-07-20 1997-02-06 Advanced Bioconcept, Inc. Cell sorting with fluorescent peptides
DE69819478T2 (de) 1997-02-03 2004-09-02 Mallinckrodt, Inc. Verfahren zum Nachweis und zur Lokalisierung maligner menschlicher Pankreastumore
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
WO1999052539A1 (en) 1998-04-10 1999-10-21 Mayo Foundation For Medical Education And Research Neo-tryptophan
WO2000078796A2 (en) 1999-06-24 2000-12-28 Mallinckrodt Inc. Labeled neurotensin derivatives with improved resistance to enzymatic degradation
WO2005016141A1 (en) * 2003-07-09 2005-02-24 California Pacific Medical Center Remote detection of substance delivery to cells
CA2676413A1 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
EP2334642B1 (en) * 2008-09-16 2014-01-01 The Regents Of The University Of California Simplified one-pot synthesis of [18f]sfb for radiolabeling
MX2011005963A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
US8586043B2 (en) * 2009-01-07 2013-11-19 Inserm ( Institut National De La Sante Et De La Recherche Medicale) Methods for treating breast cancer with inhibitors of neurotensin activation of NTSR1
EP2454272B1 (en) 2009-07-16 2017-08-23 IASON GmbH Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2066317C1 (ru) * 1990-08-20 1996-09-10 Санофи Производные амидопиразолов или их соли с органическими или минеральными кислотами или с органическими или неорганическими основаниями и фармацевтическая композиция, обладающая ингибирующей активностью в отношении нейротензина
RU2195455C2 (ru) * 1995-04-11 2002-12-27 Санофи-Синтелябо Замещенные 1-фенил-3-карбоксамиды и их фармацевтически приемлемые соли, способ их получения, промежуточные соединения и фармацевтическая композиция на их основе, обладающая сродством к человеческим рецепторам нейротензина
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
WO2011156557A2 (en) * 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor

Also Published As

Publication number Publication date
FI3712131T3 (fi) 2023-03-28
AU2013354422B2 (en) 2018-03-15
CN109320502A (zh) 2019-02-12
AU2013354422A1 (en) 2015-05-28
KR20150092300A (ko) 2015-08-12
CA2893605C (en) 2021-08-10
PL2928870T3 (pl) 2020-09-21
IL239080B (en) 2019-06-30
US20150299133A1 (en) 2015-10-22
ZA201503446B (en) 2016-01-27
CN104837819A (zh) 2015-08-12
US20210087149A1 (en) 2021-03-25
BR112015012530A2 (pt) 2017-09-12
JP7042776B2 (ja) 2022-03-28
JP6576828B2 (ja) 2019-09-18
EP3712131B1 (en) 2023-02-01
HK1210148A1 (en) 2016-04-15
EP2928870A1 (en) 2015-10-14
KR102290803B1 (ko) 2021-08-18
US20260078095A1 (en) 2026-03-19
MX2015007193A (es) 2016-03-17
WO2014086499A1 (en) 2014-06-12
SG10201704564QA (en) 2017-07-28
IL239080A0 (en) 2015-07-30
SG11201503880YA (en) 2015-06-29
PT3712131T (pt) 2023-04-04
ES2795923T3 (es) 2020-11-25
JP2019218375A (ja) 2019-12-26
PL3712131T3 (pl) 2023-05-02
US10961199B2 (en) 2021-03-30
HUE050388T2 (hu) 2020-11-30
BR112015012530B1 (pt) 2022-07-19
DK2928870T3 (da) 2020-07-13
JP2016501238A (ja) 2016-01-18
CN104837819B (zh) 2018-12-07
ES2941629T3 (es) 2023-05-24
EP2928870B1 (en) 2020-04-08
PT2928870T (pt) 2020-05-29
MX370354B (es) 2019-12-10
DK3712131T3 (da) 2023-03-20
RU2015127086A (ru) 2017-01-11
EP2740726A1 (en) 2014-06-11
CN104837819B9 (zh) 2019-07-09
CA2893605A1 (en) 2014-06-12
CN109320502B (zh) 2022-06-07
EP3712131A1 (en) 2020-09-23
HUE061839T2 (hu) 2023-08-28
WO2014086499A8 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
US20260078095A1 (en) Neurotensin receptor ligands
JP7065567B2 (ja) ニューロテンシン受容体リガンドを含むコンジュゲートおよびそれらの使用
JP5308829B2 (ja) 癌の画像化および処置
CN106573959B (zh) 修饰的环五肽及其用途
KR20250016195A (ko) 전립선-특이적 막 항원(psma) 리간드
HK40037865B (en) Neurotensin receptor ligands
HK40037865A (en) Neurotensin receptor ligands
HK40003630B (en) Neurotensin receptor ligands
HK40003630A (en) Neurotensin receptor ligands
HK1210148B (en) Neurotensin receptor ligands
JP2005068046A (ja) ソマトスタチンアナログ誘導体およびその利用
KR20250011145A (ko) 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드
Mascarin Triazole-Based Radiopeptidomimetics: Novel Neurotensin (8-13) Analogues with Increased Metabolic Stability